Physician
Presbyterian Healthcare Services
Presbyterian Healthcare Services was paid $47.63M by Medicaid between Jan 2018 and Dec 2024, across 315 billing codes. Its largest line is 99284, emergency room visit (serious) — 14% of everything it billed.
33Billing provider infoPRESBYTERIAN HEALTHCARE SERVICES
CLOVIS, NM 88101
CLOVIS, NM 88101
33aNPI1629053509assigned 12/13/2005
33bProvider typeEmergency Medicine Physician
28Total paid$47.63M
24GClaims876,823
24DCodes billed315
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Emergency Medicine Physician providers in New Mexico
Rank by total paid#3 of 39
Median peer was paid$669K
This provider vs. median71×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 163,249 | $7.81M | |
| 2019 | 135,762 | $7.09M | |
| 2020 | 85,861 | $4.76M | |
| 2021 | 99,316 | $5.07M | |
| 2022 | 129,305 | $7.08M | |
| 2023 | 148,266 | $8.37M | |
| 2024incomplete | 115,064 | $7.46M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 14% | 30,388 | 28,720 | $6.65M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 11% | 34,111 | 32,697 | $5.44M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 11% | 18,494 | 17,092 | $5.31M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.0% | 5,771 | 5,600 | $2.37M |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 3.6% | 13,419 | 12,972 | $1.72M |
| G0378 | Hospital observation service, per hour | 3.6% | 2,815 | 2,675 | $1.69M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.6% | 21,461 | 18,951 | $1.25M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.2% | 6,155 | 5,852 | $1.03M |
| 80053 | Comprehensive metabolic panel | 2.1% | 59,416 | 51,038 | $1.02M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.0% | 14,744 | 3,944 | $975K |
| 71045 | Radiologic examination, chest; single view | 2.0% | 16,296 | 15,261 | $939K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.9% | 21,250 | 17,284 | $920K |
303 more codes
| 87631 | 1.7% | 5,798 | $815K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.7% | 3,072 | $788K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.5% | 18,437 | $718K |
| 71046 | Radiologic examination, chest; 2 views | 1.4% | 10,677 | $685K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.4% | 6,813 | $649K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.4% | 14,529 | $645K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.2% | 4,559 | $557K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.2% | 57,650 | $552K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.1% | 3,893 | $511K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 1,164 | $430K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 9,114 | $416K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,084 | $402K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 4,012 | $388K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 11,581 | $305K |
| 73562 | <1% | 3,560 | $305K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 8,629 | $296K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,406 | $289K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,851 | $279K |
| 93976 | <1% | 2,401 | $277K | |
| 84484 | <1% | 15,503 | $248K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 7,219 | $243K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,537 | $239K |
| 73610 | <1% | 2,320 | $226K | |
| 59025 | Fetal non-stress test | <1% | 2,075 | $220K |
| 73030 | <1% | 2,585 | $209K | |
| 83690 | <1% | 15,758 | $205K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 3,354 | $180K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 764 | $175K |
| 96376 | <1% | 3,705 | $166K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 8,537 | $166K |
| 73130 | <1% | 2,364 | $158K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,145 | $156K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,956 | $152K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 8,604 | $148K |
| 76830 | Ultrasound, transvaginal | <1% | 1,055 | $147K |
| 73630 | <1% | 2,254 | $145K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 8,123 | $141K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,383 | $138K |
| 83605 | <1% | 10,012 | $138K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 30,084 | $125K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 1,482 | $121K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 295 | $119K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 350 | $114K |
| 73110 | <1% | 1,758 | $113K | |
| 87081 | <1% | 11,481 | $113K | |
| 81001 | <1% | 18,861 | $110K | |
| 74018 | <1% | 1,682 | $108K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,863 | $100K |
| 83735 | <1% | 13,977 | $100K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,186 | $100K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,157 | $93K |
| 87040 | <1% | 4,899 | $91K | |
| 83880 | <1% | 4,691 | $88K | |
| 76801 | <1% | 614 | $87K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 191 | $84K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 10,716 | $83K |
| 93971 | <1% | 1,117 | $82K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 631 | $81K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,189 | $80K |
| 84702 | <1% | 2,686 | $73K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,435 | $73K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,675 | $71K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 870 | $71K |
| 85027 | <1% | 9,175 | $70K | |
| 73564 | <1% | 851 | $70K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 2,336 | $66K |
| 96367 | <1% | 1,115 | $64K | |
| 72100 | <1% | 705 | $62K | |
| 81003 | <1% | 12,626 | $59K | |
| 84703 | <1% | 6,088 | $58K | |
| 71250 | <1% | 450 | $58K | |
| 74022 | <1% | 668 | $56K | |
| 73080 | <1% | 765 | $53K | |
| 36000 | <1% | 3,136 | $53K | |
| 82962 | <1% | 8,179 | $50K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,819 | $49K |
| 81025 | <1% | 4,914 | $49K | |
| J3490 | Unclassified drugs | <1% | 16,271 | $48K |
| 86140 | <1% | 12,625 | $46K | |
| 85379 | <1% | 3,110 | $46K | |
| 76770 | <1% | 523 | $46K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,219 | $45K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,218 | $45K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 107 | $42K |
| 84439 | <1% | 3,880 | $41K | |
| 73140 | <1% | 564 | $41K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 103 | $41K |
| 85610 | <1% | 7,158 | $39K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 676 | $38K |
| 74019 | <1% | 336 | $38K | |
| 73502 | <1% | 700 | $38K | |
| 0225U | <1% | 98 | $37K | |
| 87430 | <1% | 2,232 | $37K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 254 | $36K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 67 | $36K |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 38 | $36K |
| 82077 | <1% | 3,150 | $34K | |
| 94761 | <1% | 2,496 | $33K | |
| 73100 | <1% | 442 | $33K | |
| 86850 | <1% | 2,232 | $31K | |
| 87077 | <1% | 4,131 | $31K | |
| 87186 | <1% | 2,718 | $30K | |
| 97162 | <1% | 609 | $30K | |
| 82728 | <1% | 2,289 | $30K | |
| 72110 | <1% | 310 | $29K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 733 | $28K |
| 76642 | <1% | 261 | $27K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,244 | $26K |
| 82570 | <1% | 4,581 | $26K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 450 | $26K |
| 80061 | Lipid panel | <1% | 1,967 | $25K |
| 73090 | <1% | 391 | $25K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 182 | $25K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 9,584 | $24K |
| 82803 | <1% | 1,049 | $24K | |
| 83970 | <1% | 522 | $22K | |
| 83550 | <1% | 2,095 | $22K | |
| 72131 | <1% | 108 | $22K | |
| 82043 | <1% | 3,768 | $21K | |
| 87632 | <1% | 89 | $21K | |
| 73590 | <1% | 316 | $21K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 544 | $21K |
| 70486 | <1% | 99 | $21K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,477 | $20K |
| 86900 | <1% | 2,715 | $20K | |
| 94760 | <1% | 1,923 | $20K | |
| 97161 | <1% | 677 | $19K | |
| 29125 | <1% | 185 | $19K | |
| 82550 | <1% | 2,633 | $19K | |
| 90715 | <1% | 985 | $19K | |
| Q3014 | Telehealth originating site facility fee | <1% | 679 | $17K |
| 94060 | <1% | 182 | $17K | |
| J2704 | Injection, propofol, 10 mg | <1% | 3,141 | $17K |
| 99443 | <1% | 281 | $17K | |
| 12001 | <1% | 145 | $16K | |
| 51702 | <1% | 251 | $16K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 4,085 | $16K |
| 86901 | <1% | 2,712 | $16K | |
| 72040 | <1% | 180 | $16K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,760 | $16K |
| 80143 | <1% | 1,302 | $15K | |
| 76536 | <1% | 135 | $15K | |
| 80179 | <1% | 1,268 | $15K | |
| 83540 | <1% | 2,186 | $14K | |
| 85730 | <1% | 2,076 | $14K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 26 | $14K |
| 73522 | <1% | 169 | $12K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 497 | $12K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,434 | $12K |
| 86803 | <1% | 821 | $12K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 22 | $11K |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 48 | $11K |
| 86780 | <1% | 667 | $10K | |
| 93017 | <1% | 57 | $10K | |
| 80076 | <1% | 947 | $9K | |
| 81002 | <1% | 3,337 | $9K | |
| 84100 | <1% | 1,466 | $9K | |
| 81513 | <1% | 69 | $9K | |
| 94726 | <1% | 108 | $8K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,623 | $8K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 991 | $8K |
| 36591 | <1% | 284 | $8K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,286 | $8K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,299 | $8K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,806 | $8K |
| 88307 | <1% | 70 | $8K | |
| 70498 | <1% | 14 | $7K | |
| 85652 | <1% | 1,310 | $7K | |
| 87807 | <1% | 441 | $7K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 12 | $7K |
| 84550 | <1% | 1,174 | $6K | |
| 94729 | <1% | 120 | $6K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,623 | $6K |
| 70496 | <1% | 13 | $6K | |
| 71101 | <1% | 67 | $5K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 12 | $5K |
| 73620 | <1% | 77 | $5K | |
| 93970 | <1% | 32 | $5K | |
| 36600 | <1% | 211 | $5K | |
| 82140 | <1% | 385 | $5K | |
| 87070 | <1% | 384 | $5K | |
| 99205 | Prolong outpt/office vis | <1% | 48 | $5K |
| 82248 | <1% | 572 | $5K | |
| 88342 | <1% | 90 | $5K | |
| 84156 | <1% | 1,067 | $5K | |
| 96523 | <1% | 173 | $5K | |
| 88304 | <1% | 181 | $4K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 38 | $4K |
| 80074 | <1% | 93 | $4K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,595 | $4K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 14 | $4K |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 202 | $4K |
| 84112 | <1% | 63 | $4K | |
| 82607 | <1% | 253 | $4K | |
| 86762 | <1% | 266 | $4K | |
| 87340 | <1% | 352 | $4K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 97 | $4K |
| 80050 | General health panel | <1% | 186 | $3K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 510 | $3K |
| 78227 | <1% | 12 | $3K | |
| 77066 | Tomosynthesis, mammo | <1% | 30 | $3K |
| 11721 | <1% | 126 | $3K | |
| 70220 | <1% | 30 | $3K | |
| 86787 | <1% | 240 | $3K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 663 | $3K |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 281 | $3K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,570 | $3K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,580 | $2K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 812 | $2K |
| 87205 | <1% | 414 | $2K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 132 | $2K |
| 87486 | <1% | 48 | $2K | |
| 73560 | <1% | 29 | $2K | |
| 83655 | <1% | 119 | $2K | |
| 82010 | <1% | 248 | $2K | |
| 94727 | <1% | 12 | $2K | |
| 31720 | <1% | 14 | $2K | |
| 87581 | <1% | 48 | $2K | |
| 82805 | <1% | 73 | $2K | |
| 77065 | Tomosynthesis, mammo | <1% | 17 | $2K |
| 93242 | <1% | 39 | $2K | |
| 87481 | <1% | 55 | $2K | |
| 82247 | <1% | 149 | $1K | |
| 99407 | <1% | 122 | $1K | |
| 83615 | <1% | 130 | $1K | |
| 93243 | <1% | 18 | $1K | |
| 12011 | <1% | 14 | $1K | |
| 73120 | <1% | 14 | $1K | |
| 82375 | <1% | 74 | $1K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 15 | $1K |
| 97164 | <1% | 107 | $1K | |
| 83525 | <1% | 105 | $1K | |
| J1815 | Injection, insulin, per 5 units | <1% | 734 | $1K |
| 82784 | <1% | 96 | $1K | |
| 76010 | <1% | 13 | $1K | |
| 51701 | <1% | 13 | $1K | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 240 | $1K |
| 96368 | <1% | 23 | $1K | |
| 86038 | <1% | 79 | $1K | |
| 51798 | <1% | 38 | $1K | |
| 72070 | <1% | 15 | $949.01 | |
| 10060 | <1% | 13 | $881.26 | |
| 80069 | <1% | 121 | $853.54 | |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | <1% | 26 | $824.70 |
| 82746 | <1% | 64 | $761.17 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 420 | $713.71 |
| 73552 | <1% | 12 | $653.54 | |
| 90686 | <1% | 62 | $653.36 | |
| 82150 | <1% | 64 | $592.75 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 193 | $573.90 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 69 | $564.99 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 88 | $561.22 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 87 | $560.21 |
| 87210 | <1% | 87 | $505.65 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 96 | $489.81 |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | <1% | 68 | $481.33 |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 26 | $480.80 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 351 | $461.88 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 23 | $449.19 |
| 87505 | <1% | 46 | $425.94 | |
| 84132 | <1% | 79 | $384.86 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 261 | $362.10 |
| 86300 | <1% | 14 | $352.17 | |
| 93270 | <1% | 12 | $334.11 | |
| S0028 | Injection, famotidine, 20 mg | <1% | 115 | $330.90 |
| 82330 | <1% | 46 | $308.74 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 187 | $297.17 |
| 87449 | <1% | 24 | $291.69 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 89 | $285.25 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 180 | $274.82 |
| 87075 | <1% | 15 | $273.53 | |
| 86308 | <1% | 24 | $240.44 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 92 | $228.42 |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 45 | $216.53 |
| 84295 | <1% | 51 | $211.78 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 17 | $209.80 |
| 85014 | <1% | 80 | $208.75 | |
| 90670 | <1% | 122 | $208.43 | |
| 85018 | <1% | 65 | $192.01 | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 26 | $184.90 |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 28 | $176.22 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 29 | $160.45 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 72 | $134.26 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 202 | $119.04 |
| J0456 | Injection, azithromycin, 500 mg | <1% | 17 | $117.15 |
| 82947 | <1% | 47 | $114.91 | |
| J1836 | Injection, metronidazole, 10 mg | <1% | 44 | $111.81 |
| 86431 | <1% | 12 | $109.26 | |
| 97116 | <1% | 20 | $108.50 | |
| 81015 | <1% | 24 | $104.50 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 29 | $95.76 |
| 85045 | <1% | 13 | $87.76 | |
| G0008 | Administration of influenza virus vaccine | <1% | 87 | $85.21 |
| 87147 | <1% | 13 | $75.91 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 19 | $74.22 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 12 | $37.41 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 13 | $27.58 |
| 36416 | <1% | 32 | $20.61 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 12 | $20.40 |
| Q2039 | Influenza virus vaccine, not otherwise specified | <1% | 42 | $15.68 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 17 | $12.94 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 237 | $0.00 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBEAMES, BO (VP REGIONAL OPERATIONS)
| Provider | Location | Paid |
|---|---|---|
| Presbyterian Healthcare Services | Ruidoso, NM | $33.04M |
| Presbyterian Healthcare Services | Clovis, NM | $407K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.